What we do
Ipsen is a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology, neuroscience and rare diseases.
Our therapeutic areas
We achieve our goal of improving lives through close collaboration with
patient organizations, patients, caregivers, nurses, physicians, and
communities on a local and global level.
Oncology
Ipsen has a specialist portfolio in niche oncology. We have been active in this area since 1986, branching out from a solid base in neuroendocrine tumors (NETs), kidney, liver, pancreatic, prostate, bladder, and breast cancers.
Neuroscience
Ipsen continues its long-standing commitment to a multi-modal approach to treating mobility impairment in adult and pediatric patients and improving their quality of life.
Rare diseases
In the field of rare diseases, Ipsen takes a patient-focused approach to improving the lives of people affected by rare disorders and develops high-quality, innovative treatments that address unmet needs.
Consumer HealthCare
Ipsen’s long-standing expertise spans the value chain, with special expertise in gastrointestinal (GI) disorders, neurodegenerative pathologies and rheumatology, as well as a constantly expanding portfolio.
Careers at Ipsen
Ipsen offers exciting opportunities that will challenge your abilities , expand your skills and reward your contribution in a positive atmosphere of personal and professional development.
Search Ipsen positionsResearch & Development
Commitment
Ipsen’s commitment to research & development is our bold promise to patients to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines.
Read more
Research & Development
Partnerships
By partnering with Ipsen, you will gain access to a like-minded global biopharmaceutical company with powerhouse development and commercialization teams.
Investors
As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.
News Center
News Center